ADC Therapeutics SA 12th Annual Cantor Fitzgerald Global Healthcare Conference

Sure. Well, thank you so much for the question. ADC Therapeutics is a commercial-stage antibody drug conjugate company, one of the pioneers, and we are really focused on our commercialized product, ZYNLONTA, which is an anti-CD19 ADC, using a novel payload of PBD. The way this product is differentiated is it works extremely quickly. When you get to a CR, those responses tend to be very durable, and it has a manageable side effect profile with a time-limited course of therapy. It is an outpatient therapy every 3 weeks, only 30-minute infusion, so it is very simple to administer as well, both in the academic and community settings. It is also a single-agent activity, which is quite unique within DLBCL. Outside of CAR T and bispecifics, it is the only product that has ever been approved as a single agent and therefore also is combinable with other regimens.

We see the potential to not only expand into earlier lines of DLBCL, in particular with our bispecific study with glofitamab, our LOTIS-7 study, but also through our indolent lymphoma studies, which we're studying both in follicular lymphoma as well as marginal zone lymphoma.

Yeah, at the end of the day, we have an asset that's on the market that's approved that does about $75 million to $80 million a year. That's a starting point. We will be sharing data. The ASH abstracts will come out November 4 for both marginal zone lymphoma data and LOTIS-7 data, which is our combination between ZYNLONTA and the bispecific glofitamab. In prior data disclosures, we've shared best-in-class data in both of those settings, and we think that with the meaningful opportunity that we have there, with publications coming later and then getting into compendia in 2027, we do believe there'll be additional growth opportunity from our existing business, but also through some incidental use. We obviously, of course, will not promote off-label, but both of these markets have a lot of incidental use today. Finally, we think we have an opportunity even from a regulatory standpoint.

We're going to be filing for breakthrough designation for both the combination of ZYNLONTA plus glofitamab as well as in marginal zone lymphoma. We think we have a regulatory pathway to take this asset to over $600 million of peak sales. I think the value of what we have today and what we're going to have in the near term as well as in the long term for this asset is underappreciated.

Sure. Today we are approved as a monotherapy in third-line plus DLBCL. We have about a 10% share despite having actually a lower CR rate than many of the combination regimens that are currently approved there. The reason we are used is you are typically getting into your best response at the first disease assessment, which is at six weeks. So after two cycles, you are typically getting into your best response. And those CRs tend to be very durable. So the median duration of CR was not reached even two years with two years of follow-up. So they tend to be very durable. And because it is a fixed course of therapy, most patients are getting three to four cycles of monotherapy. It is actually very easy for the physician to administer and easy to manage for the patient as well. So that is where we play today.

Where we are going is a real focus on the combination with glofitamab, which is one of the approved bispecific products from Genentech Roche. It has obviously excellent efficacy and a good profile on its own. So now you are combining two of the most potent single-agent drugs together, where in the data we have released up to this point on the first 49 patients showed additive or synergistic efficacy as well as actually a very manageable safety profile. Within that data, we demonstrated in the first 49 patients a 78% complete response rate and safety that was overall manageable with lower rates and grades of CRS and ICANS than we would otherwise see with glofitamab monotherapy.

Sure. When you move beyond frontline therapy, which is pretty standard, R-CHOP or pola-R-CHP-based therapy, when you get into the second line, it's actually quite fragmented. CAR T has established itself as the most efficacious agents to date, not only because of the high rates of CR, but because of the durability of those CRs. But because of access, logistics, manufacturing requirements, the use of CAR T has actually been limited to about 20% of the second-line plus market. In second line, you get about 20% CAR T. In third line plus, you get about 20% CAR T. But the market's sort of been capped at that despite having the most efficacy.